What is the best over the counter medicine for tinnitus

1. Demeester K, van Wieringen A, Hendrickx JJ, et al. Prevalence of tinnitus and audiometric shape. BENT. 2007;3(Suppl 7):37. [PubMed] [Google Scholar]

2. Hannaford PC, Simpson JA, Bisset AF, Davis A, McKerrow W, Mills R. The prevalence of ear, nose and throat problems in the community: Results from a national cross-sectional postal survey in Scotland. Fam Pract. 2005;22(3):227. [PubMed] [Google Scholar]

3. Coles RR. Epidemiology of tinnitus: (1) Prevalence. J Laryngol Otol. 1984;9(Suppl):7. [PubMed] [Google Scholar]

4. McCombe A, Baguley D, Coles R, McKenna L, McKinney C, Windle-Taylor P. Guidelines for the grading of tinnitus severity: The results of a working group commissioned by the British Association of Otolaryngologists, Head and Neck Surgeons, 1999. Clin Otolaryngol. 2001;26(5):388. [PubMed] [Google Scholar]

5. Medical Research Council’s Institute of Hearing Research. Epidemiology of tinnitus. In: Hazell JWP, editor. Tinnitus. Churchill Livingstone; Edinburgh: 1987. pp. 46–70. [Google Scholar]

6. Hoffmann HJ, Reed GW. Epidemiology of tinnitus. In: Snow JB, editor. Tinnitus: Theory and Management. B.C. Decker; Hamilton: 2004. pp. 16–41. [Google Scholar]

7. Davis A, Fafaie E. Epidemiology of tinnitus. In: Tyler R, editor. Tinnitus Handbook. Singular Publishing Group; San Diego: 2000. pp. 1–23. [Google Scholar]

8. Axelsson A, Ringdahl A. Tinnitus - A study of its prevalence and characteristics. Br J Audiol. 1989;23(1):53–62. [PubMed] [Google Scholar]

9. Vio MM, Holme RH. Hearing loss and tinnitus: 250 Million people and a US$10 billion potential market. Drug Discov Today. 2005;10(19):1263. [PubMed] [Google Scholar]

10. Cave KM, Cornish EM, Chandler DW. Blast injury of the ear: Clinical update from the global war on terror. Mil Med. 2007;172(7):726. [PubMed] [Google Scholar]

11. Nicolas-Puel C, Faulconbridge RL, Guitton M, Puel JL, Mondain M, Uziel A. Characteristics of tinnitus and etiology of associated hearing loss: A study of 123 patients. Int Tinnitus J. 2002;8(1):37–44. [PubMed] [Google Scholar]

12. Douek E. Classification of tinnitus. In: Evered D, Lawrenson G, editors. Tinnitus Ciba Foundation Symposium 85. Pitman: Bath; 1981. pp. 4–15. [Google Scholar]

13. Moller AR. Tinnitus: Presence and future. Prog Brain Res. 2007;166:3. [PubMed] [Google Scholar]

14. Meikle MB, Griest S. Asymmetry in tinnitus perception. In: Aran JM, Dauman R, editors. Tinnitus 91: Proceedings of the Fourth International Tinnitus Seminar. Kugler Publications; Amsterdam: 1992. pp. 231–7. [Google Scholar]

15. Hallberg LR, Erlandsson SI. Tinnitus characteristics in tinnitus complainers and noncomplainers. Br J Audiol. 1993;27(1):19–27. [PubMed] [Google Scholar]

16. Tyler RS. The psychoacoustical measurement of tinnitus. In: Tyler RS, editor. Tinnitus Handbook. Singular Publishing; San Diego: 2000. pp. 149–79. [Google Scholar]

17. Loeb M, Smith R. Relation of induced tinnitus to physical characteristics of the inducing stimuli. J Acoust Soc Am. 1967;42(2):453–5. [PubMed] [Google Scholar]

18. Norena A, Micheyl C, Chery-Croze S, Collet L. Psychoacoustic characterization of the tinnitus spectrum: Implications for the underlying mechanisms of tinnitus. Audiol Neuro-Otol. 2002;7(6):358. [PubMed] [Google Scholar]

19. Kaltenbach JA. Neurophysiologic mechanisms of tinnitus. J Am Acad Audiol. 2000;11(3):125–37. [PubMed] [Google Scholar]

20. Stouffer JL, Tyler RS. Characterization of tinnitus by tinnitus patients. J Speech Hear Res. 1990;55(3):439–53. [PubMed] [Google Scholar]

21. Wegel RL, Lane CE. The auditory masking of one pure tone by another and its probable relation to the dynamics of the inner ear. Physical Rev. 1924;23(2):266–85. [Google Scholar]

22. Vernon J, Meikle M. Tinnitus, CIBA Foundation Symposium 85. Pittman: Bath; 1981. Tinnitus masking: Unresolved problems; pp. 239–62. [PubMed] [Google Scholar]

23. Henry JA, Rheinsburg B, Owens KK, Ellingson RM. Acta Oto-Laryngol. Suppl 556. 2006. New instrumentation for automated tinnitus psychoacoustic assessment; p. 34. [PubMed] [Google Scholar]

24. Davis PB, Paki B, Hanley PJ. Neuromonics Tinnitus Treatment: Third clinical trial. Ear Hear. 2007;28(2):242. [PubMed] [Google Scholar]

25. Teggi R, Bellini C, Piccioni LO, Palonta F, Bussi M. Transmeatal low-level laser therapy for chronic tinnitus with cochlear dysfunction. Audiol Neuro-Otol. 2008;14(2):115. [PubMed] [Google Scholar]

26. Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg. 1993;119(8):842. [PubMed] [Google Scholar]

27. Westerberg BD, et al. A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus. Am J Otol. 1996;17(6):896. [PubMed] [Google Scholar]

28. Penner MJ, Zhang T. Masking patterns for partially masked tinnitus. Int Tinnitus J. 1996;2:105–9. [PubMed] [Google Scholar]

29. Feldmann H. Homolateral and contralateral masking of tinnitus by noise-bands and by pure tones. Audiology. 1971;10(3):138. [PubMed] [Google Scholar]

30. Zwislocki JJ, Buining E, Glantz J. Frequency distribution of central masking. J Acoust Soc Am. 1968;43(6):1267–71. [PubMed] [Google Scholar]

31. Tyler RS, Babin R, Niebuhr D. Some observations on the masking and postmasking effects on tinnitus. J Laryngol Otol. 1984;9(Suppl):150. [Google Scholar]

32. Penner MJ. Masking of tinnitus and central masking. J Speech Hear Res. 1987;30(2):147–52. [PubMed] [Google Scholar]

33. Penner MJ, Brauth S, Hood L. The temporal course of the masking of tinnitus as a basis for inferring its origin. J Speech Hear Res. 1981;24(2):257–61. [PubMed] [Google Scholar]

34. Penner MJ, Bilger RC. Adaptation and the masking of tinnitus. J Speech Hear Res. 1989;32(2):339–46. [PubMed] [Google Scholar]

35. Wilson PH, Henry J, Bowen M, Haralambous G. Tinnitus reaction questionnaire: Psychometric properties of a measure of distress associated with tinnitus. J Speech Hear Res. 1991;34(1):197–201. [PubMed] [Google Scholar]

36. Kuk FK, Tyler RS, Russell D, Jordan H. The psychometric properties of a tinnitus handicap questionnaire. Ear Hear. 1990;11(6):434. [PubMed] [Google Scholar]

37. Newman CW, Jacobson GP, Spitzer JB. Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg. 1996;122(2):143. [PubMed] [Google Scholar]

38. Baguley DM, Andersson G. Factor analysis of the Tinnitus Handicap Inventory. Am J Audiol. 2003;12(1):31–4. [PubMed] [Google Scholar]

39. Seligmann H, Podoshin L, Ben-David J, Fradis M, Goldsher M. Drug-induced tinnitus and other hearing disorders. Drug Saf. 1996;14(3):198. [PubMed] [Google Scholar]

40. Briner W. A behavioral nosology for tinnitus. Psychol Rep. 1995;77(1):27–34. [PubMed] [Google Scholar]

41. Tyler R, Coelho C, Tao P, Ji H, Noble W, Gehringer A, Gogel S. Identifying tinnitus subgroups with cluster analysis. Am J Audiol. 2008;17(2):S176–84. [PMC free article] [PubMed] [Google Scholar]

42. Goldstein B, Shulman A. Tinnitus classification: Medical audiologic assessment. J Laryngol Otol. 1981;(4 Suppl):33. [PubMed] [Google Scholar]

43. Norena A, Cransac H, Chery-Croze S. Towards an objectification by classification of tinnitus. Clin Neurophysiol. 1999;110(4):666. [PubMed] [Google Scholar]

44. Levine RA. Typewriter tinnitus: A carbamazepine-responsive syndrome related to auditory nerve vascular compression. ORL - J Otorhinolaryngol Relat Spec. 2006;68(1):43. [PubMed] [Google Scholar]

45. Mardini MK. Ear-clicking “tinnitus” responding to carbamazepine. New Engl J Med. 1987;317(24):1542. [PubMed] [Google Scholar]

46. Rahko T, Hakkinen V. Carbamazepine in the treatment of objective myoclonus tinnitus. J Laryngol Otol. 1979;93(2):123. [PubMed] [Google Scholar]

47. Shea JJ, Harell M. Management of tinnitus aurium with lidocaine and carbamazepine. Laryngoscope. 1978;88(9, Pt. 1):1477. [PubMed] [Google Scholar]

48. Dobie RA. A review of randomized clinical trials in tinnitus. Laryngoscope. 1999;109(8):1202. [PubMed] [Google Scholar]

49. Dobie RA. Clinical trials and drug therapy for tinnitus. In: Snow JBJ, editor. Tinnitus: Theory and Management. BC Decker, Inc; Hamilton: 2004. pp. 266–77. [Google Scholar]

50. Robinson S, Viirre ES, Stein MB. Antidepressant therapy for tinnitus. In: Snow JBJ, editor. Tinnitus: Theory and Management. BC Decker, Inc; Hamilton: 2004. pp. 278–93. [Google Scholar]

51. Lobarinas E, Yang G, Sun W, et al. Salicylate- and quinine-induced tinnitus and effects of memantine. Acta Oto-Laryngol. 2006;(Suppl 556):13. [PubMed] [Google Scholar]

52. Lobarinas E, Sun W, Cushing R, Salvi R. A novel behavioral paradigm for assessing tinnitus using schedule-induced polydipsia avoidance conditioning (SIP-AC) Hear Res. 2004;190(1–2):109. [PubMed] [Google Scholar]

53. Jastreboff PJ, Brennan JF, Sasaki CT. An animal model for tinnitus. Laryngoscope. 1988;98(3):280. [PubMed] [Google Scholar]

54. Jastreboff PJ, Brennan JF, Sasaki CT. Quinine-induced tinnitus in rats. Arch Otolaryngol Head Neck Surg. 1991;117(10):1162. [PubMed] [Google Scholar]

55. Grigor RR, Spitz PW, Furst DE. Salicylate toxicity in elderly patients with rheumatoid arthritis. J Rheumatol. 1987;14(1):60. [PubMed] [Google Scholar]

56. Bateman DN, Dyson EH. Quinine toxicity. Adverse Drug React Acute Poisoning Rev. 1986;5(4):215. [PubMed] [Google Scholar]

57. Dodson KM, Sismanis A. Intratympanic perfusion for the treatment of tinnitus. Otolaryngol Clin North Am. 2004;37(5):991. [PubMed] [Google Scholar]

58. Schwab B, Lenarz T, Heermann R. Use of the round window micro cath for inner ear therapy - Results of a placebo-controlled, prospective study on chronic tinnitus. Laryngo-Rhino-Otol. 2004;83(3):164. [PubMed] [Google Scholar]

59. Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998;49:173. [PubMed] [Google Scholar]

60. Williams SH. Medications for treating alcohol dependence. Am Fam Physician (1970) 2005;72(9):1775. [PubMed] [Google Scholar]

61. Mason BJ, Crean R. Acamprosate in the treatment of alcohol dependence: Clinical and economic considerations. Expert Rev Neurother. 2007;7(11):1465. [PubMed] [Google Scholar]

62. Pierrefiche O, Daoust M, Naassila M. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology. 2004;47(1):35. [PubMed] [Google Scholar]

63. Madamba SG, Schweitzer P, Zieglgansberger W, Siggins GR. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol Clin Exp Res. 1996;20(4):651. [PubMed] [Google Scholar]

64. Berton F, Francesconi WG, Madamba SG, Zieglgansberger W, Siggins GR. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res. 1998;22(1):183. [PubMed] [Google Scholar]

65. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate. Part I Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res. 1998;22(4):802. [PubMed] [Google Scholar]

66. Zeise ML, et al. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex - Possible involvement of excitatory amino acid receptors. Eur J Pharmacol. 1993;231(1):47. [PubMed] [Google Scholar]

67. Wu JY, Jin H, Schloss JV, Faiman MD, Ningaraj NS, Foos T, Chen W. Neurotoxic effect of acamprosate, n-acetyl-homotaurine, in cultured neurons. J Biomed Sci. 2001;8(1):96. [PubMed] [Google Scholar]

68. Azevedo AA, Figueiredo RR. Tinnitus treatment with acamprosate: Double-blind study. Braz J Otorhinolaryngol. 2005;71(5):618–23. [PMC free article] [PubMed] [Google Scholar]

69. Azevedo AA, Figueiredo RR. Treatment of tinnitus with acamprosate. Prog Brain Res. 2007;166:273. [PubMed] [Google Scholar]

70. Oestreicher E, Arnold W, Ehrenberger K, Felix D. Memantine suppresses the glutamatergic neurotransmission of mammalian inner hair cells. ORL - J Otorhinolaryngol Relat Spec. 1998;60(1):18. [PubMed] [Google Scholar]

71. Guitton MJ, Pujol R, Puel JL. m-Chlorophenylpiperazine exacerbates perception of salicylate-induced tinnitus in rats. Eur J Neurosci. 2005;22(10):2675. [PubMed] [Google Scholar]

72. Milbrandt JC, Holder TM, Wilson MC, Salvi RJ, Caspary DM. GAD levels and muscimol binding in rat inferior colliculus following acoustic trauma. Hear Res. 2000;147(1–2):251. [PubMed] [Google Scholar]

73. Brozoski TJ, Spires TJ, Bauer CA. Vigabatrin, a GABA transaminase inhibitor, reversibly eliminates tinnitus in an animal model. J Assoc Res Otolaryngol. 2007;8(1):105–18. [PMC free article] [PubMed] [Google Scholar]

74. Daftary A, Shulman A, Strashun AM, Gottschalk C, Zoghbi SS, Seibyl JP. Benzodiazepine receptor distribution in severe intractable tinnitus. Int Tinnitus J. 2004;10(1):17–23. [PubMed] [Google Scholar]

75. Suneja SK, Potashner SJ, Benson CG. Plastic changes in glycine and GABA release and uptake in adult brain stem auditory nuclei after unilateral middle ear ossicle removal and cochlear ablation. Exp Neurol. 1998;151(2):273. [PubMed] [Google Scholar]

76. Kudo Y, Shibata S. Effects of caroverine and diltiazem on synaptic responses, L-glutamate-induced depolarization and potassium efflux in the frog spinal cord. Br J Pharmacol. 1984;83(3):813. [PMC free article] [PubMed] [Google Scholar]

77. Koppi S, Eberhardt G, Haller R, Koenig P. Calcium-channel-blocking agent in the treatment of acute alcohol withdrawal - Caroverine versus meprobamate in a randomized double-blind study. Neuropsychobiology. 1987;17(1–2):49. [PubMed] [Google Scholar]

78. Saletu B, Gruenberger J, Anderer P, Linzmayer L, Koenig P. Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration. Arzneim-Forsch Drug Res. 1995;45(3):217. [PubMed] [Google Scholar]

79. Ehrenberger K, Felix D. Receptor pharmacological models for inner ear therapies with emphasis on glutamate receptors: A survey. Acta Oto-Laryngol. 1995;115(2):236. [PubMed] [Google Scholar]

80. Ehrenberger K, Felix D. Caroverine depresses the activity of cochlear glutamate receptors in guinea pigs: In vivo model for drug-induced neuroprotection? Neuropharmacology. 1992;31(12):1259. [PubMed] [Google Scholar]

81. Chen Z, Duan M, Lee H, Ruan R, Ulfendahl M. Pharmacokinetics of caroverine in the inner ear and its effects on cochlear function after systemic and local administrations in Guinea pigs. Audiol Neuro-Otol. 2003;8(1):49. [PubMed] [Google Scholar]

82. Denk DM, Heinzl H, Franz P, Ehrenberger K. Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Oto-Laryngol. 1997;117(6):825. [PubMed] [Google Scholar]

83. Guitton MJ, Caston J, Ruel J, Johnson RM, Pujol R, Puel JL. Salicylate induces tinnitus through activation of cochlear NMDA receptors. J Neurosci. 2003;23(9):3944. [PMC free article] [PubMed] [Google Scholar]

84. Guitton MJ, Dudai Y. Blockade of cochlear NMDA receptors prevents long-term tinnitus during a brief consolidation window after acoustic trauma. Neural Plast (Online) 2007;2007:80904. [PMC free article] [PubMed] [Google Scholar]

85. Duckert LG, Rees TS. Placebo effect in tinnitus management. Otolaryngol Head Neck Surg. 1984;92(6):697. [PubMed] [Google Scholar]

86. Domeisen H, Hotz MA, Haeusler R. Caroverine in tinnitus treatment. Acta Oto-Laryngol. 1998;118(4):606. [PubMed] [Google Scholar]

87. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704. [PubMed] [Google Scholar]

88. Muhonen LH, Loennqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008;69(3):392. [PubMed] [Google Scholar]

89. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 2003;9(3):275. [PMC free article] [PubMed] [Google Scholar]

90. Deshpande SS, Smith CD, Filbert MG. Assessment of primary neuronal culture as a model for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug. Arch Toxicol. 1995;69(6):384. [PubMed] [Google Scholar]

91. Rammes G, Rupprecht R, Ferrari U, Zieglgaensberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001;306(1–2):81. [PubMed] [Google Scholar]

92. Oliver D, et al. Memantine inhibits efferent cholinergic transmission in the cochlea by blocking nicotinic acetylcholine receptors of outer hair cells. Mol Pharmacol. 2001;60(1):183. [PubMed] [Google Scholar]

93. Jastreboff PJ, Brennan JF, Coleman JK, Sasaki CT. Phantom auditory sensation in rats: An animal model for tinnitus. Behav Neurosci. 1988;102(6):811. [PubMed] [Google Scholar]

94. Myers EN, Bernstein JM. Salicylate ototoxicity; a clinical and experimental study. Arch Otolaryngol Head Neck Surg. 1965;82(5):483. [PubMed] [Google Scholar]

95. Peng BG, et al. Aspirin selectively augmented N-methyl-D-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice. Neurosci Lett. 2003;343(1):21. [PubMed] [Google Scholar]

96. Figueiredo RR, Langguth B, Mello de Oliveira P, Aparecida de Azevedo A. Tinnitus treatment with memantine. Otolaryngol Head Neck Surg. 2008;138(4):492. [PubMed] [Google Scholar]

97. Gilling K, Jatzke C, Wollenburg C, Vanejevs M, Kauss V, Jirgensons A, Parsons CG. A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists - In vitro characterization. J Neural Transm. 2007;114(12):1529. [PubMed] [Google Scholar]

98. Plazas PV, Savino J, Kracun S, Gomez-Casati ME, Katz E, Parsons CG, Millar NS, Elgoyhen AB. Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors. Eur J Pharmacol. 2007;566(1–3):11. [PubMed] [Google Scholar]

99. Wenzel GI, Lim HH, Staver T, Lobl T, Schloss J, Schwab B, Lenarz T. Effects of gacyclidine extracochlear perfusion on tinnitus in humans and intracochlear perfusion on ABR thresholds in Guinea pigs. [Google Scholar]

100. Srisurapanont M, Boonyanaruthee V. Alprazolam and standard antidepressants in the treatment of depression: A meta-analysis of the antidepressant effect. J Med Assoc Thail. 1997;80(3):183. [PubMed] [Google Scholar]

101. Kravitz HM, Fawcett J, Newman AJ. Alprazolam and depression: A review of risks and benefits. J Clin Psychiatry. 1993;54(Suppl):78. [PubMed] [Google Scholar]

102. Freeman AM, 3rd, Fleece L, Folks DG, et al. Alprazolam treatment of postcoronary bypass anxiety and depression. J Clin Psychopharmacol. 1986;6(1):39. [PubMed] [Google Scholar]

103. Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. J Clin Psychiatry. 1986;47(9):458. [PubMed] [Google Scholar]

104. Obata T, Yamamura HI. Modulation of GABA-stimulated chloride influx into membrane vesicles from rat cerebral cortex by triazolobenzodiazepines. Life Sci. 1988;42(6):659. [PubMed] [Google Scholar]

105. Lopez F, Miller LG, Greenblatt DJ, Schatzki A, Lumpkin M, Shader RI. Chronic low-dose alprazolam augments gamma-aminobutyric acid(A) receptor function. J Clin Psychopharmacol. 1992;12(2):119. [PubMed] [Google Scholar]

106. Huynh L, Fields S. Alprazolam for tinnitus. Ann Pharmacother. 1995;29(3):311. [PubMed] [Google Scholar]

107. Sieghart W. Pharmacology of benzodiazepine receptors: An update. J Psychiatry Neurosci. 1994;19(1):24. [PMC free article] [PubMed] [Google Scholar]

108. McLean MJ, Macdonald RL. Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture. J Pharmacol Exp Ther. 1988;244(2):789. [PubMed] [Google Scholar]

109. Kay NJ. Oral chemotherapy in tinnitus. Br J Audiol. 1981;15(2):123–4. [PubMed] [Google Scholar]

110. Busto U, Fornazzari L, Naranjo CA. Protracted tinnitus after discontinuation of long-term therapeutic use of benzodiazepines. J Clin Psychopharmacol. 1988;8(5):359. [PubMed] [Google Scholar]

111. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. New Engl J Med. 1986;315(14):854. [PubMed] [Google Scholar]

112. Gananca MM, Caovilla HH, Gananca FF, Gananca CF, Munhoz MS, da Silva ML, Serafini F. Clonazepam in the pharmacological treatment of vertigo and tinnitus. Int Tinnitus J. 2002;8(1):50–3. [PubMed] [Google Scholar]

113. Bahmad FM, Jr, Venosa AR, Oliveira CA. Benzodiazepines and GABAergics in treating severe disabling tinnitus of predominantly cochlear origin. Int Tinnitus J. 2006;12(2):140–4. [PubMed] [Google Scholar]

114. Murai K, Tyler RS, Harker LA, Stouffer JL. Review of pharmacologic treatment of tinnitus. Am J Otol. 1992;13(5):454. [PubMed] [Google Scholar]

115. Mattson RH, Petroff OAC, Rothman D, Behar K. Vigabatrin: Effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Acta Neurol Scand. 1995;92(Suppl 162):27. [PubMed] [Google Scholar]

116. Richens A. Pharmacology and clinical pharmacology of vigabatrin. J Child Neurol. 1991;(Suppl 2):S7. [PubMed] [Google Scholar]

117. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs. 2001;15(5):339. [PubMed] [Google Scholar]

118. Wu YM, et al. Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release. J Neurophysiol. 2003;89(4):2021. [PubMed] [Google Scholar]

119. Smith SE, Parvez NS, Chapman AG, Meldrum BS. The gamma-aminobutyric acid uptake inhibitor, tiagabine, is anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol. 1995;273(3):259. [PubMed] [Google Scholar]

120. Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs. 1998;55(3):437. [PubMed] [Google Scholar]

121. Zwanzger P, Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci. 2005;30(3):167. [PMC free article] [PubMed] [Google Scholar]

122. Gram L. Tiagabine: A novel drug with a GABAergic mechanism of action. Epilepsia. 1994;35(Suppl 5):S85. [PubMed] [Google Scholar]

123. Chen L, Yung WH. Effects of the GABA-uptake inhibitor tiagabine in rat globus pallidus. Exp Brain Res. 2003;152(2):263. [PubMed] [Google Scholar]

124. Potashner SJ, Suneja SK, Benson CG. Regulation of D-aspartate release and uptake in adult brain stem auditory nuclei after unilateral middle ear ossicle removal and cochlear ablation. Exp Neurol. 1997;148(1):222. [PubMed] [Google Scholar]

125. Caspary DM, Ling L, Turner JG, Hughes LF. Inhibitory neurotransmission, plasticity and aging in the mammalian central auditory system. J Exp Biol. 2008;211(Pt. 11):1781. [PMC free article] [PubMed] [Google Scholar]

126. Bauer CA, Brozoski TJ, Holder TM, Caspary DM. Effects of chronic salicylate on GABAergic activity in rat inferior colliculus. Hear Res. 2000;147(1–2):175. [PubMed] [Google Scholar]

127. Besag FM. Behavioural effects of the newer antiepileptic drugs: An update. Expert Opin Drug Saf. 2004;3(1):1. [PubMed] [Google Scholar]

128. Schwartz ML, Meyer MB, Covino BG, Narang RM, Sethi V, Schwartz AJ, Kamp P. Antiarrhythmic effectiveness of intramuscular lidocaine: Influence of different injection sites. J Clin Pharmacol. 1974;14(2):77. [PubMed] [Google Scholar]

129. Clarkson CW, Follmer CH, Ten Eick RE, Hondeghem LM, Yeh JZ. Evidence for two components of sodium channel block by lidocaine in isolated cardiac myocytes. Circ Res. 1988;63(5):869. [PubMed] [Google Scholar]

130. Courtney KR. Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther. 1975;195(2):225. [PubMed] [Google Scholar]

131. Lenkowski PW, Shah BS, Dinn AE, Lee K, Patel MK. Lidocaine block of neonatal Nav1.3 is differentially modulated by co-expression of beta1 and beta3 subunits Eur J Pharmacol 2003, 467(1–3): 23 3 is differentially modulated by co-expression of beta1 and beta3 subunits. Eur J Pharmacol. 2003;467(1–3):23. [PubMed] [Google Scholar]

132. Josephson IR. Lidocaine blocks Na, Ca and K currents of chick ventricular myocytes. J Mol Cell Cardiol. 1988;20(7):593. [PubMed] [Google Scholar]

133. Yu M, Chen L. Modulation of major voltage- and ligand-gated ion channels in cultured neurons of the rat inferior colliculus by lidocaine. Acta Pharmacol Sin. 2008;29(12):1409. [PubMed] [Google Scholar]

134. Barany R. Die Beinflussung des Ohrensausens durch intravenös injizierte Lokalanaestetica. Acta Oto-Laryngol. 1935;23:201. [PubMed] [Google Scholar]

135. Melding PS, Goodey RJ, Thorne PR. The use of intravenous lignocaine in the diagnosis and treatment of tinnitus. J Laryngol Otol. 1978;92(2):115. [PubMed] [Google Scholar]

136. Martin FW, Colman BH. Tinnitus: A double-blind crossover controlled trial to evaluate the use of lignocaine. Clin Otolaryngol. 1980;5(1):3. [PubMed] [Google Scholar]

137. Sanchez TG, Balbani AP, Bittar RS, Bento RF, Camara J. Lidocaine test in patients with tinnitus: Rationale of accomplishment and relation to the treatment with carbamazepine. Auris Nasus Larynx. 1999;26(4):411. [PubMed] [Google Scholar]

138. Duckert LG, Rees TS. Treatment of tinnitus with intravenous lidocaine: A double-blind randomized trial. Otolaryngol Head Neck Surg. 1983;91(5):550. [PubMed] [Google Scholar]

139. Reyes SA, Salvi RJ, Burkard RF, Coad ML, Wack DS, Galantowicz PJ, Lockwood AH. Brain imaging of the effects of lidocaine on tinnitus. Hear Res. 2002;171(1–2):43. [PubMed] [Google Scholar]

140. Kallio H, Niskanen ML, Havia M, Neuvonen PJ, Rosenberg PH, Kentala E. I. V ropivacaine compared with lidocaine for the treatment of tinnitus. Br J Anaesth. 2008;101(2):261. [PubMed] [Google Scholar]

141. Haginomori S, Makimoto K, Araki M, Kawakami M, Takahashi H. Effect of lidocaine injection of EOAE in patients with tinnitus. Acta Oto-Laryngol. 1995;115(4):488. [PubMed] [Google Scholar]

142. Baguley DM, Jones S, Wilkins I, Axon PR, Moffat DA. The inhibitory effect of intravenous lidocaine infusion on tinnitus after translabyrinthine removal of vestibular schwannoma: A double-blind, placebo-controlled, crossover study. Otol Neurotol. 2005;26(2):169. [PubMed] [Google Scholar]

143. Cathcart JM. Assessment of the value of tocainide hydrochloride in the treatment of tinnitus. J Laryngol Otol. 1982;96(11):981. [PubMed] [Google Scholar]

144. Hulshof JH, Vermeij P. The value of tocainide in the treatment of tinnitus. A double-blind controlled study. Arch Oto-Rhino-Laryngol. 1985;241(3):279–83. [PubMed] [Google Scholar]

145. Emmett JR, Shea JJ. Treatment of tinnitus with tocainide hydrochloride. Otolaryngol Head Neck Surg. 1980;88(4):442. [PubMed] [Google Scholar]

146. Blayney AW, Phillips MS, Guy AM, Colman BH. A sequential double blind cross-over trial of tocainide hydrochloride in tinnitus. Clin Otolaryngol. 1985;10(2):97. [PubMed] [Google Scholar]

147. Lenarz T. Treatment of tinnitus with lidocaine and tocainide. Scand Audiol Suppl. 1986;26:49–51. [PubMed] [Google Scholar]

148. Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets. 2003;7(6):737. [PubMed] [Google Scholar]

149. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strobaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal KV7 channels. J Pharmacol Exp Ther. 2005;314(1):282. [PubMed] [Google Scholar]

150. Lobarinas E, Dalby-Brown W, Stolzberg D, Mirza N, Salvi R. Effects of the BK agonists BMS-204352 and the enantiomeric compound (“R-enantiomer”) on transient, salicylate induced tinnitus in rats. [Google Scholar]

151. Munro G, Erichsen HK, Mirza NR. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology. 2007;53(5):609. [PubMed] [Google Scholar]

152. Israel M, Beaudry P. Carbamazepine in psychiatry: A review. Can J Psychiatry. 1988;33(7):577. [PubMed] [Google Scholar]

153. Hirschfeld RM, Kasper S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol. 2004;7(4):507. [PubMed] [Google Scholar]

154. Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther. 1975;18(6):733. [PubMed] [Google Scholar]

155. Taylor JC, Brauer S, Espir ML. Long-term treatment of trigeminal neuralgia with carbamazepine. Postgrad Med J. 1981;57(663):16. [PMC free article] [PubMed] [Google Scholar]

156. Herrera JM, Sramek JJ, Costa JF. Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug Intel Clin Pharm. 1987;21(4):355. [PubMed] [Google Scholar]

157. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pharmacol. 1985;27(5):549. [PubMed] [Google Scholar]

158. Kuo CC, Chen RS, Lu L, Chen RC. Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications. Mol Pharmacol. 1997;51(6):1077. [PubMed] [Google Scholar]

159. Cardenas CA, Cardenas CG, de Armendi AJ, Scroggs RS. Carbamazepine interacts with a slow inactivation state of NaV1.8-like sodium channels Neurosci Lett 2006, 408(2): 129 8-like sodium channels. Neurosci Lett. 2006;408(2):129. [PubMed] [Google Scholar]

160. Dailey JW, Reith ME, Steidley KR, Milbrandt JC, Jobe PC. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia. 1998;39(10):1054. [PubMed] [Google Scholar]

161. Zona C, Tancredi V, Palma E, Pirrone GC, Avoli M. Potassium currents in rat cortical neurons in culture are enhanced by the antiepileptic drug carbamazepine. Can J Physiol Pharmacol. 1990;68(4):545. [PubMed] [Google Scholar]

162. Ambrosio AF, et al. Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology. 1999;38(9):1349. [PubMed] [Google Scholar]

163. Donaldson I. Tegretol: A double blind trial in tinnitus. J Laryngol Otol. 1981;95(9):947. [PubMed] [Google Scholar]

164. Hulshof JH, Vermeij P. The value of carbamazepine in the treatment of tinnitus. ORL - J Otorhinolaryngol Relat Spec. 1985;47(5):262. [PubMed] [Google Scholar]

165. Marks NJ, Onisiphorou C, Trounce JR. The effect of single doses of amylobarbitone sodium and carbamazepine in tinnitus. J Laryngol Otol. 1981;95(9):941. [PubMed] [Google Scholar]

166. Melding PS, Goodey RJ. The treatment of tinnitus with oral anticonvulsants. J Laryngol Otol. 1979;93(2):111. [PubMed] [Google Scholar]

167. Zheng Y, Hooton K, Smith PF, Darlington CL. Carbamazepine reduces the behavioural manifestations of tinnitus following salicylate treatment in rats. Acta Oto-Laryngol. 2008;128(1):48. [PubMed] [Google Scholar]

168. Liu J, Li X, Wang L, Dong Y, Han H, Liu G. Effects of salicylate on serotoninergic activities in rat inferior colliculus and auditory cortex. Hear Res. 2003;175(1–2):45. [PubMed] [Google Scholar]

169. Liu Y, Zhang H, Li X, Wang Y, Lu H, Qi X, Ma C, Liu J. Inhibition of voltage-gated channel currents in rat auditory cortex neurons by salicylate. Neuropharmacology. 2007;53(7):870. [PubMed] [Google Scholar]

170. Wang HT, Luo B, Zhou KQ, Xu TL, Chen L. Sodium salicylate reduces inhibitory postsynaptic currents in neurons of rat auditory cortex. Hear Res. 2006;215(1–2):77. [PubMed] [Google Scholar]

171. Menkes DB, Larson PM. Sodium valproate for tinnitus. J Neurol Neurosurg Psychiatry. 1998;65(5):803. [PMC free article] [PubMed] [Google Scholar]

172. Reeves RR, Mustain DW, Pendarvis JE. Valproate-induced tinnitus misinterpreted as psychotic symptoms. South Med J. 2000;93(10):1030. [PubMed] [Google Scholar]

173. Goodey R. Drug treatment for tinnitus. Prog Brain Res. 2007;166:237. [PubMed] [Google Scholar]

174. Sivenius J, Kalviainen R, Ylinen A, Riekkinen P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia. 1991;32(4):539. [PubMed] [Google Scholar]

175. Levendoglu F, et al. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine. 2004;29(7):743. [PubMed] [Google Scholar]

176. Smith DG, Ehde DM, Hanley MA, et al. Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. J Rehabil Res Dev. 2005;42(5):645. [PubMed] [Google Scholar]

177. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: A double-blind randomized placebo-controlled study. Clin Ter (Rome) 2000;151(3):145. [PubMed] [Google Scholar]

178. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;46(3):409. [PubMed] [Google Scholar]

179. Rock DM, Kelly KM, Macdonald RL. Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons. Epilepsy Res. 1993;16(2):89. [PubMed] [Google Scholar]

180. Honmou O, Kocsis JD, Richerson GB. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res. 1995;20(3):193. [PubMed] [Google Scholar]

181. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol. 1996;39(1):95. [PubMed] [Google Scholar]

182. Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA. 2008;105(9):3628. [PMC free article] [PubMed] [Google Scholar]

183. Zapp JJ. Gabapentin for the treatment of tinnitus: A case report. Ear Nose Throat J. 2001;80(2):114. [PubMed] [Google Scholar]

184. Shulman A. Gabapentin and tinnitus relief. Int Tinnitus J. 2008;14(1):1–5. [PubMed] [Google Scholar]

185. Bauer CA, Brozoski TJ. Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model. J Assoc Res Otolaryngol. 2001;2(1):54–64. [PMC free article] [PubMed] [Google Scholar]

186. Witsell DL, Hannley MT, Stinnet S, Tucci DL. Treatment of tinnitus with gabapentin: A pilot study. Otol Neurotol. 2007;28(1):11. [PubMed] [Google Scholar]

187. Bakhshaee M, Ghasemi M, Azarpazhooh M, Khadivi E, Rezaei S, Shakeri M, Tale M. Gabapentin effectiveness on the sensation of subjective idiopathic tinnitus: A pilot study. Eur Arch Oto-Rhino-Laryngol. 2008;265(5):525. [PubMed] [Google Scholar]

188. Piccirillo JF, Finnell J, Vlahiotis A, Chole RA, Spitznagel E., Jr Relief of idiopathic subjective tinnitus: Is gabapentin effective? Arch Otolaryngol Head Neck Surg. 2007;133(4):390. [PubMed] [Google Scholar]

189. Bauer CA, Brozoski TJ. Effect of gabapentin on the sensation and impact of tinnitus. Laryngoscope. 2006;116(5):675. [PubMed] [Google Scholar]

190. Gross G, Xin X, Gastpar M. Trimipramine: Pharmacological reevaluation and comparison with clozapine. Neuropharmacology. 1991;30(11):1159. [PubMed] [Google Scholar]

191. Juorio AV, Li XM, Boulton AA. The effects of chronic trimipramine treatment on biogenic amine metabolism and on dopamine D2, 5-HT2 and tryptamine binding sites in rat brain. Gen Pharmacol. 1990;21(5):759. [PubMed] [Google Scholar]

192. Mihail RC, Crowley JM, Walden BE, Fishburne J, Reinwall JE, Zajtchuk JT. The tricyclic trimipramine in the treatment of subjective tinnitus. Ann Otol Rhinol Laryngol. 1988;97(2 Pt 1):120. [PubMed] [Google Scholar]

193. Gracious B, Wisner KL. Nortriptyline in chronic fatigue syndrome: A double blind, placebo-controlled single case study. Biol Psychiatry. 1991;30(4):405. [PubMed] [Google Scholar]

194. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep. 2003;7(1):51. [PubMed] [Google Scholar]

195. Atkinson JH, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998;76(3):287. [PubMed] [Google Scholar]

196. Anderson J, Lambert NG, Pigott PV. An evaluation of fluphenazine with nortriptyline in anxiety and depression. Practitioner. 1972;208(246):511–7. [PubMed] [Google Scholar]

197. Sullivan MD, Dobie RA, Sakai CS, Katon WJ. Treatment of depressed tinnitus patients with nortriptyline. Ann Otol Rhinol Laryngol. 1989;98(11):867. [PubMed] [Google Scholar]

198. Sullivan M, Katon W, Russo J, Dobie R, Sakai C. A randomized trial of nortriptyline for severe chronic tinnitus. Effects on depression, disability, and tinnitus symptoms. Arch Intern Med. 1993;153(19):2251. [PubMed] [Google Scholar]

199. Katon W, Sullivan M, Russo J, Dobie R, Sakai C. Depressive symptoms and measures of disability: A prospective study. J Affect Disord. 1993;27(4):245. [PubMed] [Google Scholar]

200. Stein DJ, Davidson J, Seedat S, Beebe K. Paroxetine in the treatment of post-traumatic stress disorder: Pooled analysis of placebo-controlled studies. Expert Opin Pharmacother. 2003;4(10):1829. [PubMed] [Google Scholar]

201. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995;167(3):374. [PubMed] [Google Scholar]

202. Denys D, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;23(6):568. [PubMed] [Google Scholar]

203. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berlin) 1987;93(2):193. [PubMed] [Google Scholar]

204. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs) Int Clin Psychopharmacol. 1994;9(Suppl 1):19. [PubMed] [Google Scholar]

205. Robinson SK, Viirre ES, Bailey KA, Gerke MA, Harris JP, Stein MB. Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med. 2005;67(6):981. [PubMed] [Google Scholar]

206. Parnes SM. Current concepts in the clinical management of patients with tinnitus. Eur Arch Oto-Rhino-Laryngol. 1997;254(9–10):406. [PubMed] [Google Scholar]

207. Kingery WS, Davies MF, Clark JD. A substance P receptor (NK1) antagonist can reverse vascular and nociceptive abnormalities in a rat model of complex regional pain syndrome type II. Pain. 2003;104(1–2):75. [PubMed] [Google Scholar]

208. Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH, Sethna NF, MacLean DB. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther. 1998;64(5):562. [PubMed] [Google Scholar]

209. Vass Z, Nuttall AL, Coleman JK, Miller JM. Capsaicin-induced release of substance P increases cochlear blood flow in the guinea pig. Hear Res. 1995;89(1–2):86. [PubMed] [Google Scholar]

210. Sun W, Ding DL, Wang P, Sun J, Jin X, Salvi RJ. Substance P inhibits potassium and calcium currents in inner ear spiral ganglion neurons. Brain Res. 2004;1012(1–2):82. [PubMed] [Google Scholar]

211. Holliday SM, Plosker GL. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs Aging. 1993;3(3):278. [PubMed] [Google Scholar]

212. Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D, RoyByrne P, Phillips K, DuPont IJ. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol. 1999;19(2):172. [PubMed] [Google Scholar]

213. Hirschfeld RM. Sertraline in the treatment of anxiety disorders. Depress Anxiety. 2000;11(4):139. [PubMed] [Google Scholar]

214. Hesslinger B, Van de Loo A, Klecha D, Harter M, Schmidt-Schweda S. Depression and panic disorder after heart transplantation - Treatment with sertraline. Pharmacopsychiatry. 2002;35(1):31. [PubMed] [Google Scholar]

215. Guthrie SK. Sertraline: A new specific serotonin reuptake blocker. DICP. 1991;25(9):952. [PubMed] [Google Scholar]

216. Schmidt A, Lebel L, Koe BK, Seeger T, Heym J. Sertraline potently displaces (+)-[3H]3-PPP binding to sigma sites in rat brain. Eur J Pharmacol. 1989;165(2–3):335. [PubMed] [Google Scholar]

217. Robinson S. Antidepressants for treatment of tinnitus. Prog Brain Res. 2007;166:263. [PubMed] [Google Scholar]

218. Miller MJ, Sadowska-Krowicka H, Jeng AY, et al. Substance P levels in experimental ileitis in guinea pigs: effects of misoprostol. Am J Physiol. 1993;265(2 Pt 1):G321. [PubMed] [Google Scholar]

219. Gullikson GW, Anglin CP, Kessler LK, Smeach S, Bauer RF, Dajani EZ. Misoprostol attenuates aspirin-induced changes in potential difference and associated damage in canine gastric mucosa. Clin Invest Med. 1987;10(3):145. [PubMed] [Google Scholar]

220. Roth SH. Misoprostol in the prevention of NSAID-induced gastric ulcer: A multicenter, double-blind, placebo-controlled trial. J Rheumatol. 1990;20(Suppl):20. [PubMed] [Google Scholar]

221. Hall R, Duarte-Gardea M, Harlass F. Oral versus vaginal misoprostol for labor induction. Obstet Gynecol. 2002;99(6):1044. [PubMed] [Google Scholar]

222. Widomski D, et al. The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. Immunopharmacol Immunotoxicol. 1997;19(2):165. [PubMed] [Google Scholar]

223. Briner W, House J, O’Leary M. Synthetic prostaglandin E1 misoprostol as a treatment for tinnitus. Arch Otolaryngol Head Neck Surg. 1993;119(6):652. [PubMed] [Google Scholar]

224. Akkuzu B, Yilmaz I, Cakmak O, Ozluoglu LN. Efficacy of misoprostol in the treatment of tinnitus in patients with diabetes and/or hypertension. Auris Nasus Larynx. 2004;31(3):226. [PubMed] [Google Scholar]

225. Naoumova RP, Dunn S, Rallidis L, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res. 1997;38(7):1496. [PubMed] [Google Scholar]

226. Gresser U, Gathof BS. Atorvastatin: Gold standard for prophylaxis of myocardial ischemia and stroke - Comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res. 2004;9(1):1. [PubMed] [Google Scholar]

227. Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, Black DM. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a randomized, double-masked study. Clin Ther. 1996;18(5):853. [PubMed] [Google Scholar]

228. Sugiyama M, et al. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels. 2005;20(4):133. [PubMed] [Google Scholar]

229. Wang H, Lynch JR, Song P, Yang HJ, Yates RB, Mace B, Warner DS, Guyton JR, Laskowitz DT. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol. 2007;206(1):59. [PubMed] [Google Scholar]

230. Olzowy B, Canis M, Hempel JM, Mazurek B, Suckfull M. Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: Results of a prospective, randomized, double-blind clinical trial. Otol Neurotol. 2007;28(4):455. [PubMed] [Google Scholar]

231. Wu CT, Wong CS, Yeh CC, Borel CO. Treatment of cerebral vasospasm after subarachnoid hemorrhage - A review. Acta Anaesthesiol Taiwan. 2004;42(4):215–22. [PubMed] [Google Scholar]

232. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev (CD-ROM) 2006;3:CD001449. [PubMed] [Google Scholar]

233. Scriabine A, van den Kerckhoff W. Pharmacology of nimodipine. A review. Ann N Y Acad Sci. 1988;522:698. [PubMed] [Google Scholar]

234. Theopold HM. Nimodipine (Bay e 9736) a new therapy concept in diseases of the inner ear? Laryngo-Rhino-Otol. 1985;64(12):609. [PubMed] [Google Scholar]

235. Wang H, Jiang S, Yang W, Han D. Evaluating effects of some medicine on tinnitus with animal behavioral model in rats. Zhonghua Er Bi Yan Hou Ke Za Zhi. 2000;35(5):331–4. [PubMed] [Google Scholar]

236. Jastreboff PJ, Brennan JF. Specific effects of nimodipine on the auditory system. Ann N Y Acad Sci. 1988;522:716. [Google Scholar]

237. Davies E, Knox E, Donaldson I. The usefulness of nimodipine, an L-calcium channel antagonist, in the treatment of tinnitus. Br J Audiol. 1994;28(3):125–9. [PubMed] [Google Scholar]

238. Hutcheon DE, Leonard G. Diuretic and antihypertensive actions of furosemide. J Clin Pharmacol J New Drugs. 1967;7(1):26–33. [PubMed] [Google Scholar]

239. Shiozaki A, Miyazaki H, Niisato N, et al. Furosemide, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state. J Physiol Sci. 2006;56(6):401. [PubMed] [Google Scholar]

240. Sakaguchi N, Crouch JJ, Lytle C, Schulte BA. Na-K-Cl cotransporter expression in the developing and senescent gerbil cochlea. Hear Res. 1998;118(1–2):114. [PubMed] [Google Scholar]

241. Chen H, Sun D. The role of Na-K-Cl co-transporter in cerebral ischemia. Neurol Res. 2005;27(3):280. [PubMed] [Google Scholar]

242. Kolbaev SN, Sharonova IN, Vorobjev VS, Skrebitsky VG. Mechanisms of GABA(A) receptor blockade by millimolar concentrations of furosemide in isolated rat Purkinje cells. Neuropharmacology. 2002;42(7):913. [PubMed] [Google Scholar]

243. Rybak LP, Morizono T. Effect of furosemide upon endolymph potassium concentration. Hear Res. 1982;7(2):223. [PubMed] [Google Scholar]

244. Risey JA, Guth PS, Amedee RG. Furosemide distinguishes central and peripheral tinnitus. Int Tinnitus J. 1995;1(2):99–103. [PubMed] [Google Scholar]

245. Futaki T, Kitahara M, Morimoto M. A comparison of the furosemide and glycerol tests for Meniere’s disease. With special reference to the bilateral lesion. Acta Oto-Laryngol. 1977;83(3–4):272. [PubMed] [Google Scholar]

246. Kuchar DL, O’Rourke MF. High dose furosemide in refractory cardiac failure. Eur Heart J. 1985;6(11):954. [PubMed] [Google Scholar]

247. Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ - Br Med J (Clin Res Ed) 2006;333(7565):420. [PMC free article] [PubMed] [Google Scholar]

248. Huic M, Vrhovac B, Macolic-Sarinic V, Francetic I, Bakran I, Giljanovic S. How safe are bioequivalence studies in healthy volunteers? Therapie. 1996;51(4):410. [PubMed] [Google Scholar]

249. Wallach DP. Studies on the GABA pathway. I The inhibition of gamma-aminobutyric acid-alpha-ketoglutaric acid transaminase in vitro and in vivo by U-7524 (amino-oxyacetic acid) Biochem Pharmacol. 1961;5:323. [PubMed] [Google Scholar]

250. Kerwin R, Pycock C. Baclofen (beta-p-chlorophenyl-gamma-aminobutyric acid) enhances [3H]gamma-aminobutyric acid (3H-GABA) release from rat globus pallidus in vitro. J Pharm Pharmacol. 1978;30(10):622. [PubMed] [Google Scholar]

251. Bobbin RP, Gondra MI. Effect of intracochlear aminooxyacetic acid on cochlear potentials and endolymph composition. Ann Otol Rhinol Laryngol. 1975;84(2 Pt 1):192. [PubMed] [Google Scholar]

252. Reed HT, Meltzer J, Crews P, Norris CH, Quine DB, Guth PS. Amino-oxyacetic acid as a palliative in tinnitus. Arch Otolaryngol. 1985;111(12):803. [PubMed] [Google Scholar]

253. Guth PS, Risey J, Briner W, et al. Evaluation of amino-oxyacetic acid as a palliative in tinnitus. Ann Otol Rhinol Laryngol. 1990;99(1):74. [PubMed] [Google Scholar]

254. McCabe BF. Central aspects of drugs for motion sickness and vertigo. Adv Otorhinolaryngol. 1973;20:458. [PubMed] [Google Scholar]

255. Kranke P, et al. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: A quantitative systematic review. Anesth Analg. 2002;95(1):133. [PubMed] [Google Scholar]

256. Miranda HF, Silva WI, Wolstenholme WW, Cuevas N. Selective antagonism by pirenzepine and N-methyl-scopolamine on muscarinic receptor subtypes of the rat vas deferens. Gen Pharmacol. 1988;19(3):417. [PubMed] [Google Scholar]

257. Dohanich GP, Johnson AE, Nock B, McEwen BS, Feder HH. Distribution of cholinergic muscarinic binding sites in guinea-pig brain as determined by in vitro autoradiography of [3H]N-methyl scopolamine binding. Eur J Pharmacol. 1985;119(1–2):9. [PubMed] [Google Scholar]

258. Metherate R, Ashe JH, Weinberger NM. Acetylcholine modifies neuronal acoustic rate-level functions in guinea pig auditory cortex by an action at muscarinic receptors. Synapse (NY) 1990;6(4):364. [PubMed] [Google Scholar]

259. Whipple MR, Drescher DG. Muscarinic receptors in the cochlear nucleus and auditory nerve of the guinea pig. J Neurochem. 1984;43(1):192. [PubMed] [Google Scholar]

260. Wallhausser-Franke E, Cuautle-Heck B, Wenz G, Langner G, Mahlke C. Scopolamine attenuates tinnitus-related plasticity in the auditory cortex. NeuroReport. 2006;17(14):1487. [PubMed] [Google Scholar]

261. Lobarinas E, Sun W, Stolzberg D, Lu J, Salvi R. Human brain imaging of tinnitus and animal models. Semin Hear. 2008;29(4):333–49. [PMC free article] [PubMed] [Google Scholar]

262. Timmerman H. Calcium modulation and clinical effect. Profile of cyclandelate. Drugs. 1987;33(Suppl 2):1. [PubMed] [Google Scholar]

263. Siniatchkin M, Gerber WD, Vein A. Clinical efficacy and central mechanisms of cyclandelate in migraine: A double-blind placebo-controlled study. Funct Neurol. 1998;13(1):47. [PubMed] [Google Scholar]

264. Middleton B, Middleton A, White DA, Bell GD. Dietary cyclandelate decreases pre-established atherosclerosis in the rabbit. Atherosclerosis. 1984;51(2–3):171. [PubMed] [Google Scholar]

265. Holstein N. Ginkgo special extract EGb 761 in tinnitus therapy. An overview of results of completed clinical trials. Fortschr Med Orig. 2001;118(4):157–64. [PubMed] [Google Scholar]

266. Huang MH, Huang CC, Ryu SJ, Chu NS. Sudden bilateral hearing impairment in vertebrobasilar occlusive disease. Stroke. 1993;24(1):132. [PubMed] [Google Scholar]

267. Memin Y. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients. Drugs. 1987;33(Suppl 2):120. [PubMed] [Google Scholar]

268. Hester TO, Theilman G, Green W, Jones RO. Cyclandelate in the management of tinnitus: A randomized, placebo- controlled study. Otolaryngol Head Neck Surg. 1998;118(3 Pt 1):329. [PubMed] [Google Scholar]

269. Memo M, Battaini F, Spano PF, Trabucchi M. Sulpiride and the role of dopaminergic receptor blockade in the antipsychotic activity of neuroleptics. Acta Psychiatr Scand. 1981;63(4):314. [PubMed] [Google Scholar]

270. Imafuku J. The characterization of [3H]sulpiride binding sites in rat striatal membranes. Brain Res. 1987;402(2):331. [PubMed] [Google Scholar]

271. Jastreboff PJ, Hazell JWP. A neurophysiological approach to tinnitus: Clinical implications. Br J Audiol. 1993;27(1):7–17. [PubMed] [Google Scholar]

272. Lockwood AH, Salvi RJ, Coad ML, Towsley ML, Wack DS, Murphy BW. The functional neuroanatomy of tinnitus: Evidence for limbic system links and neural plasticity. Neurology. 1998;50(1):114. [PubMed] [Google Scholar]

273. Larson ER, Ariano MA. D3 and D2 dopamine receptors: Visualization of cellular expression patterns in motor and limbic structures. Synapse (NY) 1995;20(4):325. [PubMed] [Google Scholar]

274. Lopez-Gonzalez MA, Esteban-Ortega F. Tinnitus dopaminergic pathway. Ear noises treatment by dopamine modulation. Med Hypotheses. 2005;65(2):349. [PubMed] [Google Scholar]

275. Lopez-Gonzalez MA, Santiago AM, Esteban-Ortega F. Sulpiride and melatonin decrease tinnitus perception modulating the auditolimbic dopaminergic pathway. J Otolaryngol. 2007;36(4):213. [PubMed] [Google Scholar]

276. Lincoln GA, Tortonese DJ. Does melatonin act on dopaminergic pathways in the mediobasal hypothalamus to mediate effects of photoperiod on prolactin secretion in the ram? Neuroendocrinology. 1995;62(5):425. [PubMed] [Google Scholar]

277. Nguyen-Legros J, Chanut E, Versaux-Botteri C, Simon A, Trouvin JH. Dopamine inhibits melatonin synthesis in photoreceptor cells through a D2-like receptor subtype in the rat retina: Biochemical and histochemical evidence. J Neurochem. 1996;67(6):2514. [PubMed] [Google Scholar]

278. Lopez-Gonzalez MA, Moliner-Peiro F, Alfaro-Garcia J, Esteban-Ortega F. Sulpiride plus hydroxyzine decrease tinnitus perception. Auris Nasus Larynx. 2007;34(1):23. [PubMed] [Google Scholar]

279. Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol. 2004;27(4, Suppl 1):I14. [PMC free article] [PubMed] [Google Scholar]

280. Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev. 2007;15(2):76. [PubMed] [Google Scholar]

281. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone. 2005;7(1):47. [PubMed] [Google Scholar]

282. Mazurek B, Haupt H, Szczepek AJ, Sandmann J, Gross J, Klapp BF, Kiesewetter H, Kalus U, Stoever T, Caffier PP. Evaluation of vardenafil for the treatment of subjective tinnitus: A controlled pilot study. J Negat Results Biomed. 2009;8(1):3. [PMC free article] [PubMed] [Google Scholar]

283. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L. : Chemistry, efficacy, safety, and uses. J Food Sci. 2008;73(1):R14. [PubMed] [Google Scholar]

284. Morgenstern C, Biermann E. The efficacy of Ginkgo special extract EGb 761 in patients with tinnitus. Int J Clin Pharmacol Ther. 2002;40(5):188. [PubMed] [Google Scholar]

285. Jastreboff PJ, Zhou S, Jastreboff MM, Kwapisz U, Gryczynska U. Attenuation of salicylate-induced tinnitus by Ginkgo biloba extract in rats. Audiol Neuro-Otol. 1997;2(4):197. [PubMed] [Google Scholar]

286. Coles R. Trial of an extract of Ginkgo biloba (EGB) for tinnitus and hearing loss [letter] Clin Otolaryngol. 1988;13(6):501. [PubMed] [Google Scholar]

287. Holgers KM, Axelsson A, Pringle I. Ginkgo biloba extract for the treatment of tinnitus. Audiology. 1994;33(2):85. [PubMed] [Google Scholar]

288. Smith PF, Zheng Y, Darlington CL. Ginkgo biloba extracts for tinnitus: More hype than hope? J Ethnopharmacol. 2005;100(1–2):95. [PubMed] [Google Scholar]

289. Drew S, Davies E. Effectiveness of Ginkgo biloba in treating tinnitus: Double blind, placebo controlled trial. BMJ - Br Med J (Clin Res Ed) 2001;322(7278):73. [PMC free article] [PubMed] [Google Scholar]

290. Patterson MB, Balough BJ. Review of pharmacological therapy for tinnitus. Int Tinnitus J. 2006;12(2):149–59. [PubMed] [Google Scholar]

291. Rejali D, Sivakumar A, Balaji N. Ginkgo biloba does not benefit patients with tinnitus: A randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. Clin Otolaryngol Allied Sci. 2004;29(3):226. [PubMed] [Google Scholar]

292. Jan JE, Reiter RJ, Wasdell MB, Bax M. The role of the thalamus in sleep, pineal melatonin production, and circadian rhythm sleep disorders. J Pineal Res. 2009;46(1):1. [PubMed] [Google Scholar]

293. Seggie J, Werstiuk ES, Grota L. Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum. Prog Neuro-Psychopharmacol Biol Psychiatry. 1987;11(2–3):325. [PubMed] [Google Scholar]

294. Berra B, Rizzo AM. Melatonin: Circadian rhythm regulator, chronobiotic, antioxidant and beyond. Clin Dermatol. 2009;27(2):202. [PubMed] [Google Scholar]

295. Jou MJ, Peng TI, Yu PZ, Jou SB, Reiter RJ, Chen JY, Wu HY, Chen CC, Hsu LF. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res. 2007;43(4):389. [PubMed] [Google Scholar]

296. Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res. 2000;28(2):73. [PubMed] [Google Scholar]

297. Bas E, Martinez-Soriano F, Lainez JM, Marco J. An experimental comparative study of dexamethasone, melatonin and tacrolimus in noise-induced hearing loss. Acta Oto-Laryngol. 2009;129(4):385. [PubMed] [Google Scholar]

298. Rosenberg SI, Silverstein H, Rowan PT, Olds MJ. Effect of melatonin on tinnitus. Laryngoscope. 1998;108(3):305. [PubMed] [Google Scholar]

299. Megwalu UC, Finnell JE, Piccirillo JF. The effects of melatonin on tinnitus and sleep. Otolaryngol Head Neck Surg. 2006;134(2):210. [PubMed] [Google Scholar]

300. McFadden SL, Ding D, Burkard RF, Jiang H, Reaume AG, Flood DG, Salvi RJ. Cu/Zn SOD deficiency potentiates hearing loss and cochlear pathology in aged 129, CD-1 mice. J Comp Neurol. 1999;413(1):101. [PubMed] [Google Scholar]

301. Kaltenbach JA, Rachel JD, Mathog TA, Zhang J, Falzarano PR, Lewandowski M. Cisplatin-induced hyperactivity in the dorsal cochlear nucleus and its relation to outer hair cell loss: Relevance to tinnitus. J Neurophysiol. 2002;88(2):699. [PubMed] [Google Scholar]

302. Rubio ME, Juiz JM. Chemical anatomy of excitatory endings in the dorsal cochlear nucleus of the rat: Differential synaptic distribution of aspartate aminotransferase, glutamate, and vesicular zinc. J Comp Neurol. 1998;399(3):341. [PubMed] [Google Scholar]

303. Zirpel L, Parks TN. Zinc inhibition of group I mGluR-mediated calcium homeostasis in auditory neurons. J Assoc Res Otolaryngol. 2001;2(2):180–7. [PMC free article] [PubMed] [Google Scholar]

304. Shambaugh GE., Jr Zinc for tinnitus, imbalance, and hearing loss in the elderly. Am J Otol. 1986;7(6):476. [PubMed] [Google Scholar]

305. Gersdorff M, Robillard T, Stein F, Declaye X, Van der Bemden S. The zinc sulfate overload test in patients suffering from tinnitus associated with low serum zinc. Preliminary report. Acta Oto-Rhino-Laryngol Belg. 1987;41(3):498. [PubMed] [Google Scholar]

306. Coelho CB, Tyler R, Hansen M. Zinc as a possible treatment for tinnitus. Prog Brain Res. 2007;166:279. [PubMed] [Google Scholar]

307. Ochi K, Kinoshita H, Kenmochi M, Nishino H, Ohashi T. Zinc deficiency and tinnitus. Auris Nasus Larynx. 2003;30(Suppl):S25. [PubMed] [Google Scholar]

308. Arda HN, Tuncel U, Akdogan O, Ozluoglu LN. The role of zinc in the treatment of tinnitus. Otol Neurotol. 2003;24(1):86. [PubMed] [Google Scholar]

309. Paaske PB, Pedersen CB, Kjems G, Sam IL. Zinc therapy of tinnitus. A placebo-controlled study. Ugeskr Laeg. 1990;152(35):2473. [PubMed] [Google Scholar]

310. Yetiser S, Tosun F, Satar B, Arslanhan M, Akcam T, Ozkaptan Y. The role of zinc in management of tinnitus. Auris Nasus Larynx. 2002;29(4):329. [PubMed] [Google Scholar]

311. Levine RA, Nam EC, Melcher J. Somatosensory pulsatile tinnitus syndrome: somatic testing identifies a pulsatile tinnitus subtype that implicates the somatosensory system. Trends Amplif. 2008;12(3):242–53. [PMC free article] [PubMed] [Google Scholar]

312. Kirchmann M, Thomsen LL, Olesen J. Basilar-type migraine: Clinical, epidemiologic, and genetic features. Neurology. 2006;66(6):880. [PubMed] [Google Scholar]

313. Weissman JL, Hirsch BE. Imaging of tinnitus: A review. Radiology. 2000;216(2):342. [PubMed] [Google Scholar]

314. Branstetter BFT, Weissman JL. The radiologic evaluation of tinnitus. Eur Radiol. 2006;16(12):2792. [PubMed] [Google Scholar]

315. Pinchoff RJ, Burkard RF, Salvi RJ, Coad ML, Lockwood AH. Modulation of tinnitus by voluntary jaw movements. Am J Otol. 1998;19(6):785. [PubMed] [Google Scholar]

316. Simmons R, Dambra C, Lobarinas E, Stocking C, Salvi R. Head, neck and eye movements that modulate tinnitus. Sem Hear. 2008;29:361–70. [PMC free article] [PubMed] [Google Scholar]

317. Hanley PJ, Davis PB, Paki B, Quinn SA, Bellekom SR. Treatment of tinnitus with a customized, dynamic acoustic neural stimulus: Clinical outcomes in general private practice. Ann Otol Rhinol Laryngol. 2008;117(11):791. [PubMed] [Google Scholar]

318. Henry JA, Schechter MA, Zaugg TL, et al. Clinical trial to compare tinnitus masking and tinnitus retraining therapy. Acta Oto-Laryngol. 2006;(Suppl 556):64. [PubMed] [Google Scholar]

319. Henry JA, Schechter MA, Zaugg TL, et al. Outcomes of clinical trial: Tinnitus masking versus tinnitus retraining therapy. J Am Acad Audiol. 2006;17(2):104–32. [PubMed] [Google Scholar]

320. Dobie RA, Sullivan MD, Katon WJ, Sakai CS, Russo J. Antidepressant treatment of tinnitus patients. Interim report of a randomized clinical trial. Acta Oto-Laryngol. 1992;112(2):242. [PubMed] [Google Scholar]

321. Paul AK, Lobarinas E, Simmons R, et al. Metabolic imaging of rat brain during pharmacologically-induced tinnitus. NeuroImage. 2009;44(2):312. [PMC free article] [PubMed] [Google Scholar]

What helps tinnitus go away?

What is the best pill to take for tinnitus?

What vitamin deficiency causes ringing in the ears?

Does anything actually work for tinnitus?